GLUE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Monte Rosa Therapeutics Inc (GLUE) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators do not show a clear upward trend, and the stock has been underperforming recently. While the company has shown revenue growth and improved financial metrics, it remains unprofitable. The lack of significant positive news or trading signals, combined with neutral sentiment from hedge funds and insiders, suggests that this is not an ideal entry point for investment. A hold strategy is recommended until stronger catalysts or upward momentum emerge.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 41.413, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 17.365), with resistance at R1: 19.939.
Revenue growth of 38.54% YoY in Q3 2025 is also a positive sign.
The stock has been declining recently, with a -3.55% regular market change and further drops in pre- and post-market trading. No recent news or significant insider/hedge fund activity. The company remains unprofitable with negative net income and EPS.
In Q3 2025, revenue increased by 38.54% YoY to $12.768M, net income improved by 13.50% YoY to -$27.081M, and EPS increased by 13.79% YoY to -0.33. Gross margin remained at 100%. While financials are improving, the company is still not profitable.
Wells Fargo upgraded the stock to Overweight from Equal Weight with a $22 price target. The upgrade is based on the company's catalyst path in 2026, including MRT-8102 Phase 1 update and Novartis' plans for MRT-6160.
